Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OS4T-eIL-12
- Development stage
- Preclinical
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
OS4T-eIL-12 is a **lipid nanoparticle (LNP) formulation containing engineered interleukin-12 (eIL-12) mRNA**, designed for systemic delivery to treat glioblastoma (GBM)[1]. The drug leverages the OS4T lipid nanoparticle platform to facilitate targeted mRNA delivery to brain tissue, inducing expression of IL-12 in situ. The mechanism leads to increased local immune activation, the upregulation of M1 macrophage/microglia markers (CD80, CD86, iNOS), enhanced activation of CD8^+^ T cells, and reduced regulatory CD4^+^ T cells, resulting in significant tumor growth inhibition and extended survival in preclinical models[1]. OS4T-eIL-12 is being investigated primarily for GBM in animal studies; there is no evidence from current results of clinical trials in humans.
- Brand names
- OS4T-eIL-12OS-4T-eIL-12OS 4T-eIL-12
- Other names
- OS4T-eIL-12OS-4T-eIL-12OS 4T-eIL-12
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on OS4T-eIL-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OS4T-eIL-12.